Urrence of the genomic breakpoints was analyzed in both groups. In

Urrence of the genomic breakpoints was analyzed in both groups. In the 1p/19q-co-deleted tumors, by definition, the chromosome 1 and 19 centromeric breakpoints were observed simultaneously within all of the tumors (Figure S1, Panel A). In the non-1p/19q-co-deleted tumors, the most common co-occurrence of genomic breakpoints involved chromosome 9 (44683090) and chromosome 19 (32455280) in 6/15 cases (Figure S1, Panel B).Copy Neutral LOH in Anaplastic OligodendrogliomasFigure 2. Frequency of genomic alterations in the 1p/19q-co-deleted anaplastic oligodendrogliomas on the top part of the panel and non-1p/19q-co-deleted anaplastic oligodendrogliomas on the bottom part. Panel A. Genomic gain, genomic loss and uniparental disomy are indicated in red, green and blue, respectively. Panel B. High-level amplification and homozygous deletion are indicated in red and green, respectively. Panel C. Genomic breakpoints are indicated with a black dot across the genome. 22948146 doi:10.1371/journal.pone.0045950.gTable 1. Genomic alterations containing candidate genes in 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).Chromosome region Homozygous deletion chr19_32455280_32670285 chr19_32679064_32877033 chr9_44683090_44770712 chr4_69097539_69135491 chr9_44779627_45338079 chr4_69139402_69258302 chr6_67075448_67105019 chr9_21963422_22123716 High-level amplification chr21_46815526_46935542 chr11_133914145_134445626 chr21_46746267_46812570 chr8_39350791_39457081 chr11_133844842_133909403 chr12_21054_213172 chr3_38411_267992 chr8_146163558_146264218 doi:10.1371/journal.pone.0045950.tN 6 5 5 3 3 2 2 2 4 3 3 3 2 2 2GenesZNFTMPRSS11B FAM27C YTHDCCDKN2B-AS1-CDKN2A-CDKN2B-C9orf53 NCRNA00175-SLC19A1-COL18A1 VPS26B-GLB1L3-NCAPD3-ACAD8-B3GAT1-LOC283177-THYN1-JAM3-GLB1LADAM3A-ADAM18 LOC100128239 LOC100288778-IQSEC3-FAM138D CHL1 ZNF252-TMED10P1-C8orf77-ZNFCopy Neutral LOH in Anaplastic OligodendrogliomasTable 2. Genomic alterations containing candidate genes in non 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).Chromosome region Homozygous deletion chr9_22534004_22615342 chr9_21413394_21951866 chr9_21998026_22531137 chr9_22617742_23432605 High-level amplification chr7_54622953_55307516 chr12_56366092_56463559 chr3_38411_267992 chr7_54577787_54620005 chr7_55312776_55466552 chr7_61504406_62203847 chr8_121235610_121468055 doi:10.1371/journal.pone.0045950.tN 3 2 2 2 3 2 2 2 2 2GenesIFNE-IFNA1-MIR31-MTAP-LOC554202 CDKN2B-AS1-CDKN2B-DMRTAEGFR-VSTM2A-SEC61G CDK2-RAB5B-RPS26-IKZF4-SUOX CHL1 VSTM2A LANCLMTBP-MRPL13-COL14AClinico-molecular correlationsNo statistically significant difference was observed between the cohort of patients with 1p/19q-co-deleted tumors versus the cohort of patients with non-1p/19q-co-deleted tumors in terms of: (i) sexratio (1.3 versus 1.5, p = 0.9), (ii) median age at MedChemExpress SPDB diagnosis (50.0 versus 49.9 years, p = 0.9) and (iii) median KPS at diagnosis (90 versus 90 , p = 0.9).Figure 3. An anaplastic oligodendroglioma with AZ 876 chemical information CDKN2A expression and normal CDKN2A gene copy number and allelic statuses. Panel A. Top part: Genomic profile with the copy number status. Middle part: Genomic profile with the allelic frequencies. Bottom part: The genomic profile including genomic loss (in green), normal copy number status (light blue) and copy neutral loss of heterozygosity (dark blue). Panel B. Chromosome 9 and the allelic frequencies (the arrow indicates the CDKNA locus). Panel C.Urrence of the genomic breakpoints was analyzed in both groups. In the 1p/19q-co-deleted tumors, by definition, the chromosome 1 and 19 centromeric breakpoints were observed simultaneously within all of the tumors (Figure S1, Panel A). In the non-1p/19q-co-deleted tumors, the most common co-occurrence of genomic breakpoints involved chromosome 9 (44683090) and chromosome 19 (32455280) in 6/15 cases (Figure S1, Panel B).Copy Neutral LOH in Anaplastic OligodendrogliomasFigure 2. Frequency of genomic alterations in the 1p/19q-co-deleted anaplastic oligodendrogliomas on the top part of the panel and non-1p/19q-co-deleted anaplastic oligodendrogliomas on the bottom part. Panel A. Genomic gain, genomic loss and uniparental disomy are indicated in red, green and blue, respectively. Panel B. High-level amplification and homozygous deletion are indicated in red and green, respectively. Panel C. Genomic breakpoints are indicated with a black dot across the genome. 22948146 doi:10.1371/journal.pone.0045950.gTable 1. Genomic alterations containing candidate genes in 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).Chromosome region Homozygous deletion chr19_32455280_32670285 chr19_32679064_32877033 chr9_44683090_44770712 chr4_69097539_69135491 chr9_44779627_45338079 chr4_69139402_69258302 chr6_67075448_67105019 chr9_21963422_22123716 High-level amplification chr21_46815526_46935542 chr11_133914145_134445626 chr21_46746267_46812570 chr8_39350791_39457081 chr11_133844842_133909403 chr12_21054_213172 chr3_38411_267992 chr8_146163558_146264218 doi:10.1371/journal.pone.0045950.tN 6 5 5 3 3 2 2 2 4 3 3 3 2 2 2GenesZNFTMPRSS11B FAM27C YTHDCCDKN2B-AS1-CDKN2A-CDKN2B-C9orf53 NCRNA00175-SLC19A1-COL18A1 VPS26B-GLB1L3-NCAPD3-ACAD8-B3GAT1-LOC283177-THYN1-JAM3-GLB1LADAM3A-ADAM18 LOC100128239 LOC100288778-IQSEC3-FAM138D CHL1 ZNF252-TMED10P1-C8orf77-ZNFCopy Neutral LOH in Anaplastic OligodendrogliomasTable 2. Genomic alterations containing candidate genes in non 1p/19q co-deleted anaplastic oligodendrogliomas in at least two tumors (as identified by genoCN).Chromosome region Homozygous deletion chr9_22534004_22615342 chr9_21413394_21951866 chr9_21998026_22531137 chr9_22617742_23432605 High-level amplification chr7_54622953_55307516 chr12_56366092_56463559 chr3_38411_267992 chr7_54577787_54620005 chr7_55312776_55466552 chr7_61504406_62203847 chr8_121235610_121468055 doi:10.1371/journal.pone.0045950.tN 3 2 2 2 3 2 2 2 2 2GenesIFNE-IFNA1-MIR31-MTAP-LOC554202 CDKN2B-AS1-CDKN2B-DMRTAEGFR-VSTM2A-SEC61G CDK2-RAB5B-RPS26-IKZF4-SUOX CHL1 VSTM2A LANCLMTBP-MRPL13-COL14AClinico-molecular correlationsNo statistically significant difference was observed between the cohort of patients with 1p/19q-co-deleted tumors versus the cohort of patients with non-1p/19q-co-deleted tumors in terms of: (i) sexratio (1.3 versus 1.5, p = 0.9), (ii) median age at diagnosis (50.0 versus 49.9 years, p = 0.9) and (iii) median KPS at diagnosis (90 versus 90 , p = 0.9).Figure 3. An anaplastic oligodendroglioma with CDKN2A expression and normal CDKN2A gene copy number and allelic statuses. Panel A. Top part: Genomic profile with the copy number status. Middle part: Genomic profile with the allelic frequencies. Bottom part: The genomic profile including genomic loss (in green), normal copy number status (light blue) and copy neutral loss of heterozygosity (dark blue). Panel B. Chromosome 9 and the allelic frequencies (the arrow indicates the CDKNA locus). Panel C.